TB-500

TB-500 is a synthetic peptide analog developed for preclinical research investigation. Published studies have examined its actin-sequestering properties and interactions with structural cellular proteins in in vitro assay models. Pepticore supplies this compound exclusively as a laboratory reference material. No biological outcomes or suitability for human use is implied or established.

Thymosin Beta-4 was first identified during thymus tissue studies in the 1960s. TB-500 was subsequently developed as a synthetic fragment to enable focused investigation of actin-binding peptide interactions in laboratory settings. Peer-reviewed preclinical research has since examined its structural binding properties across multiple in vitro assay formats.

Peer-reviewed literature has examined TB-500's binding characteristics across the following in vitro assay categories:

• Cytoskeletal assays: actin-binding and filament interaction studies
• Vascular cell culture models: endothelial receptor interaction profiling
• Extracellular matrix assays: structural protein interaction studies
• Epithelial cell culture models: barrier function assay research

All findings referenced here are sourced from third-party peer-reviewed publications. Pepticore makes no independent claims regarding biological activity, efficacy, or outcomes for this compound.

Published literature examining TB-500's structural binding properties is accessible via PubMed (CAS: 885340-08-9).